Journal
MABS
Volume 5, Issue 1, Pages 80-85Publisher
LANDES BIOSCIENCE
DOI: 10.4161/mabs.22593
Keywords
vNAR; IgNAR; single domain antibodies; rhTNF alpha; shark; neutralization; Heterodontus francisci
Categories
Funding
- SILANES S.A. de C.V.
- CONACYT
Ask authors/readers for more resources
The therapeutic use of single domain antibodies (sdAbs) is a promising new approach because these small antibodies maintain antigen recognition and neutralization capacity, have thermal and chemical stability and have good solubility. In this study, using phage display technology, we isolated a variable domain of a IgNAR (vNAR) from a Heterodontus francisci shark immunized against the recombinant human cytokine TNF alpha (rhTNF alpha). One clone T43, which expresses the vNAR protein in the periplasmic space, was isolated from the fourth round of panning. T43 had the capacity to recognize rhTNF and neutralize it in vitro, indicating that T43 has potential as a therapeutic that can be used for diseases in which this pro-inflammatory cytokine needs to be controlled.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available